Last reviewed · How we verify
Prophylaxis: Diphtheria, tetanus and pertussis
This vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens. Used for Prophylaxis of diphtheria, Prophylaxis of tetanus, Prophylaxis of pertussis.
At a glance
| Generic name | Prophylaxis: Diphtheria, tetanus and pertussis |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated or toxoid forms of diphtheria and tetanus toxins along with pertussis antigens (acellular or whole-cell), which trigger both humoral and cell-mediated immune responses. Upon vaccination, the immune system generates protective antibodies (primarily IgG) against these pathogens and establishes immunological memory, preventing infection or severe disease if exposure occurs.
Approved indications
- Prophylaxis of diphtheria
- Prophylaxis of tetanus
- Prophylaxis of pertussis
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fatigue or malaise
- Myalgia
- Headache
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (PHASE4)
- Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction (PHASE4)
- Adapting Motivational Interviewing for Maternal Immunizations (MI4MI) (NA)
- Predictive Value of Heart Rate Variability on Cardiorespiratory Events
- Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: